

Vulvar Cancer Awareness Day: Vaccination


Elmar A. Joura

Medical University of Vienna - Comprehensive Cancer Center

Department of Gynecologic Oncology

HPV types in vulvar cancer

Percent



Anti-HPV 16/18 Efficacy – Comparison with the Placebo Cohort of the qHPV Vaccine Program

Supportive Analysis – Per Protocol Efficacy Population

	V503		FUTURE	
	9vHPV	qHPV	qHPV	Placebo
	n	n	n	n
HPV 16/18-related LSIL	0 / 5715	2 / 5732	7 / 7738	133 / 7714
HPV 16/18-related HSIL+	1 / 5715	0 / 5732	2 / 7738	100 / 7714
HPV 16/18-related H- VIN or VaIN	0 / 5762	2 / 5789	0 / 7772	19 / 7744



The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

E.A. Joura, A.R. Giuliano, O.-E. Iversen, C. Bouchard, C. Mao, J. Mehlsen, E.D. Moreira, Jr., Y. Ngan, L.K. Petersen, E. Lazcano-Ponce, P. Pitisuttithum, J.A. Restrepo, G. Stuart, L. Woelber, Y.C. Yang, J. Cuzick, S.M. Garland, W. Huh, S.K. Kjaer, O.M. Bautista, I.S.F. Chan, J. Chen, R. Gesser, E. Moeller, M. Ritter, S. Vuocolo, and A. Luxembourg, for the Broad Spectrum HPV Vaccine Study*

ABSTRACT

BACKGROUND

The investigational 9-valent viruslike particle vaccine against human papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6, 11, 16, and 18) and five additional oncogenic types (31, 33, 45, 52, and 58). Here we present the results of a study of the efficacy and immunogenicity of the 9vHPV vaccine in women 16 to 26 years of age.

METHODS

The authors' full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Joura at the Department of Gynecology and Obstetrics, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, Austria, or at elmar.joura@meduniwien.ac.at.



HPV 31/33/45/52/58 Vaccine Efficacy

Per-Protocol Efficacy Population- end of study

Endpoint	9vHPV n	qHPV n	Vaccine Efficacy
All CIN	2 / 5949	110 / 5943	98.2% (93.7, 99.7)
> CIN2	1 / 5949	35 / 5943	97.1% (83.5, 99.9)
> CIN3	0 / 5949	7 / 5,943	100% (39.4, 100)
All VIN, VaIN	1 / 6009	18 / 6012	94.4% (67.7, 99.7)
> H- VIN, VaIN	0 / 6009	3 / 6012	100.0% (-71.5, 100)

Number needed to vaccinate (NNV) Nonavalente HPV VAccine

- Cancer <100
- Precancer <10
- Genital warts <10
- Any HPV-disease 4

Table 1: NNV estimates by case of diseases prevented by Gardasil 9 in France

Diseases Prevented (SmPC)	Number of cases occurring in the cohort	Proportion attributed to HPV types 6/11/16/18/31/33/45/52/58	NNV to avert one case with Gardasil 9
Cervical cancer	3400	90%	126
Anal cancer	804	79%	683
Vaginal cancer	232	61%	2744
Vulvar cancer	753	16%	3162
Any cancer*	5189	-	99
CIN2/3	47062	82%	10
AIN2+	196	78%	2843
VaIN2+	445	74%	1168
VIN2+	2531	82%	186
Any high grade precancerous lesion*	50234	-	9
Genital warts	56318	85%	8
Any disease*	111740	-	4

*diseases included in the label of the vaccine (i.e. penile and oropharyngeal cancers not included in estimations)

Girls, France

www.ecsvd.eu



REGISTRATION NOW OPEN!

13th Congress of the **ECSVD**
European College for the Study of Vulva Disease
September 10 - 12, 2020
Vienna, Austria



MEDIZINISCHE
UNIVERSITÄT WIEN